Abstract
COMBI-APlus (NCT03551626) evaluated an adapted pyrexia management algorithm in patients (pts) with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib (D + T). The study showed significant improvement in the composite pyrexia events compared to that in COMBI-AD. Here we report the updated long-term toxicity profile and relapse-free survival (RFS) from COMBI-APlus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
